Global Cancer Generics Market to Witness Double Digit Growth

Backed by patent expiration and active private sector participation, the global cancer generics market is likely to grow at a CAGR of 27% during 2010-2014, says RNCOS.

NOIDA, India (prHWY.com) March 5, 2012 - According to our new research report, "Cancer Generics Market Analysis", the global market for cancer generics holds a tremendous growth potential mainly due to patent expiration on key products. As the market has witnessed a plethora of product launches and M&A's in recent times, the private sector participation is likely to strengthen in the years to come. With the imminent introduction of a regulatory pathway for biogenerics, the global market for cancer generics is anticipated to grow at a CAGR of around 27% during 2010-2014.

The report has revealed the existence of a number of key cancer generics in the market that exhibits strong performance and holds significant prospects in the future. Arimidex, for instance, is a prescription medication used to treat breast cancer in postmenopausal women. The drug is manufactured by major companies, such as Mylan Pharmaceuticals, Roxane Laboratories, Teva Pharmaceuticals, and others. Moreover, it is believed that the generic version of Arimidex would cost around 59% less than its branded version.

The report, "Cancer Generics Market Analysis", identifies and analyzes all the rising trends including the significant drivers propelling the growth of the cancer generics market worldwide. It effectively examines key industrial developments and competitive scenarios to enable clients understand the market structure and companies' strategies. As there remains a high level of unmet need in the market, the report also investigates the pipeline portfolio of oncology drugs.

The global market for cancer generics into oral generic cancer drugs and generic cancer injectables has been covered extensively and analysis on key drugs under the categorized segments has been studied. It also provides a realistic picture of the cost structure associated with key branded and generic cancer drugs and difference among them. Moreover, a brief overview of product innovations and key industry activity has also been covered in the report. Overall, the report seeks to provide clients with an optimum source of reliable statistics and important developments in the global cancer generics market.

For FREE SAMPLE of this report visit: http://www.rncos.com/Report/IM353.htm

Some of our Related Reports are:

- Generic Drug Market in Canada (http://www.rncos.com/Report/IM598.htm)
- Booming Generics Drug Market in India(http://www.rncos.com/Report/IM256.htm)
- UK Generics Market Analysis(http://www.rncos.com/Report/IM313.htm)
- Japanese Generic Market Forecast to 2013(http://www.rncos.com/Report/IM170.htm)
- Booming US Generic Drug Market(http://www.rncos.com/Report/IM589.htm)

Check Related REPORTS on: http://www.rncos.com/Healthcare_Industry.htm

About RNCOS

RNCOS specializes in Industry intelligence and creative solutions for contemporary business segments. Our professionals analyze the industry and its various components, with a comprehensive study of the changing market behavior. Our accuracy and data precision proves beneficial in terms of pricing and time management that assist the intending consultants in meeting their objectives in a cost-effective and timely manner.

###

Tag Words: global cancer deaths

Categories: Health

Press Release Contact
B-129, Sector 6 Noida - 201301
91-120-4224-700
91-120-4224-707

Link To This Press Release:

URL HTML Code